// App-Quantinova.ai

TPS4589 : A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.

Researchers

Presenter

  • Andrea Borghese Apolo

Principal Investigators

  • Ravi Amrit Madan

  • Peter L. Choyke

  • Maria Liza Lindenberg

  • Karen A. Kurdziel

  • Les Folio

  • William Douglas Figg

  • Piyush K. Agarwal

  • Donald P. Bottaro

  • William L. Dahut

  • James L. Gulley

  • John Joseph Wright

  • Kattie Khadar

  • Jane B. Trepel

  • Jeffrey Schlom

  • Philip M. Arlen

  • Maria Merino

  • Seth M. Steinberg

Medical Centers

  • Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.

  • Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD

  • Urologic Oncology Branch, National Cancer Institute, Bethesda, MD

  • Molecular Imaging Program, CCR, NCI, NIH, Bethesda, MD

  • Radiation Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • National Cancer Institute, Rockville, MD

  • Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01688999

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved